Last reviewed · How we verify
NCT05299749
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
NA trial testing stg-rt-fMRI-Neurofeeback in Schizophrenia in 104 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Boston VA Research Institute, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 104 |
| Start date | 1 March 2022 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- stg-rt-fMRI-Neurofeeback
- sham-rt-fMRI-Neurofeedback
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Auditory Hallucination — all drugs for Auditory Hallucination →
- Treatment-resistant Schizophrenia — all drugs for Treatment-resistant Schizophrenia →
Sponsor
Boston VA Research Institute, Inc.
Who can join
Adults 18 to 55, any sex, with Schizophrenia or Auditory Hallucination. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05299749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Boston VA Research Institute, Inc. trials
Trials by the same sponsor.
- NCT05800782 — Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
- NCT05028998 — COVID-19-Related Opioid Treatment Policy Evaluation · unknown
- NCT04799340 — Computer-based Training of Face Recollection to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
- NCT04331535 — The Genomic Medicine at VA Study · NA · unknown
- NCT04225130 — Decreasing Suicide Risk Among Service Members With Posttraumatic Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05299749 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston VA Research Institute, Inc.
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05299749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing